Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, single-arm, phase II study to evaluate the efficacy and safety of CS1001 monotherapy for Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma (ENKTL)


Clinical Trial Description

Eligible subjects with rr-NKTL after prior asparaginase-based chemotherapy or chemo radiotherapy are planned to receive CS1001 1200 mg intravenous infusion every three weeks until progression of disease, intolerable toxicity, consent withdrawn, death. The primary endpoint of this trial is objective response rate (ORR), as assessed by independent radiological review committee (IRRC) based on Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03595657
Study type Interventional
Source CStone Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date June 12, 2018
Completion date March 20, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05343377 - A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma N/A